
## 1 Supplementary Figure S6



2

Supplementary Figure S6. αCTLA-4<sup>DLE</sup> promotes broad combination activity in diverse 3 4 tumor-bearing mouse models. (a) Tumor growth of C57BL/6 mice bearing subcutaneous KPC 5 tumors (n=10-15 mice/group) treated with  $\alpha$ CTLA-4<sup>DLE</sup> or isotype alone or in combination with 6 gemcitabine, cisplatin, and nab-paclitaxel. (b) C57BL/6 mice bearing B16F1.OVA tumors treated 7 with αCTLA-4<sup>DLE</sup> and αPD-1 (ICB), and/or HSC70-OVA-TRP2 vaccine plus QS21 and CpG (TAA 8 vax). (c) C57BL/6 mice bearing subcutaneous B16F1.OVA tumors treated with OVA-specific CD8 9 T cells (ACT), ICB, or isotype antibody. Data analyzed by mixed-effects models with matched 10 data followed by Tukey's multiple comparisons test (a) or pairwise log-rank test (b, c).